ow-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study - Imatinib in scleroderma

AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI0 个研究点开始时间: 2007年10月4日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.SSc as defined above
•2.Presence of active interstitial alveolitis as defined above
•3.Resistance to conventional immunosuppressive treatment as defined above
•4.Age 18-80 years
•5.Ability to give an informed consent
•6.Use of an acceptable method of birth control (if applicable). Pregnancy will be ruled out before study beginning.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Connective tissue diseases other than SSc
•2.Smoking habit
•3.Pregnancy or lactation
•4.HBV or HCV infection
•5.Hepatic Disease (ALT or ALP >1.5 fold above normal levels)
•6.Moderate or Severe Renal Failure (creatinina clearance <59ml/min)
•7.Severe Heart Failure, with Ejection Fraction ≤35% measured by echocardiography
•8.Thyroid disease with clinical evidence of hyperthyroidism or hypothyroidism treated with substitutive therapy

发起方

AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI